CCM
TNXP icon

Condor Capital Management’s Tonix Pharmaceuticals TNXP Stock Holding History

Condor Capital Management’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1
Closed -$3.9K – 236
2022
Q4 		$3.9K Buy
+1
New +$8.63K ﹤0.01% 240

Other funds holding TNXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Condor Capital Management's TNXP Position: Q1 2023 in Review

Condor Capital Management sold out of Tonix Pharmaceuticals (TNXP) in Q1 2023, closing a stake of 1 share — an estimated $3.9K sold.

Condor Capital Management first reported a position in TNXP in Q4 2022 and held it in 1 quarter. The position peaked at $3.9K in Q4 2022. 18 funds tracked by Wall St. Rank hold TNXP as of Q1 2023.

  • Condor Capital Management reported no remaining Tonix Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Condor Capital Management sold 1 Tonix Pharmaceuticals share in Q1 2023, an estimated $3.9K.
  • Condor Capital Management first reported a position in Tonix Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Condor Capital Management's Tonix Pharmaceuticals position peaked at $3.9K in Q4 2022.
  • 18 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2023.

Based on Condor Capital Management's 13F filing for Q1 2023, filed 10 May 2023.